Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva

Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva

Fibrodysplasia ossificans progressiva (FOP) is an ultrarare congenital disease that progresses through intermittent episodes of bone formation at ectopic sites. FOP patients carry heterozygous gene point mutations in activin A receptor type I <i>ACVR1</i>, encoding the bone morphogenetic...

Full description

Bibliographic Details
Main Authors: Francesc Ventura, Eleanor Williams, Makoto Ikeya, Alex N. Bullock, Peter ten Dijke, Marie-José Goumans, Gonzalo Sanchez-Duffhues
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Biomedicines
Subjects:
activin
ALK2
BMP
bone
FOP
repurposed drug
Online Access:https://www.mdpi.com/2227-9059/9/2/213

Similar Items

Similar Items